Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q3

4574.TEDINET S100S6X1
Period2023-01-01 → 2023-09-30
Filed2023-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥4.4bn2023-01-01 → 2023-09-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥3.4bn2022-01-01 → 2022-09-30Cons.Net sales
Operating income−¥444m2023-01-01 → 2023-09-30Cons.Operating income
Operating income−¥2.8bn2022-01-01 → 2022-09-30Cons.Operating income
Ordinary income−¥589m2023-01-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.9bn2022-01-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥537m2023-01-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥3.2bn2022-01-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥562m2023-01-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥562m2023-01-01 → 2023-09-30Cons.Profit loss
Net income−¥3.2bn2022-01-01 → 2022-09-30Cons.Profit loss
Total assets¥15.8bnat 2023-09-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥16.5bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥6.0bnat 2023-09-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.8bnat 2023-09-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥9.8bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
EPS (basic)¥-12.092023-01-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-0.982023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-72.972022-01-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-8.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio61.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-09-30−¥738m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥724m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-09-30−¥643m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-09-30¥4m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-09-30−¥17m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-09-30¥3.7bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-09-30¥955m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-09-30¥4.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-09-30¥293m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-09-30−¥893m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥976m
jpcrp040300-q3r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥1.8bn
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentrevenue external2022-01-01 → 2022-09-30¥5m
jpcrp040300-q3r_E22560-000Other Business Linesreportable segmentsegment profit2022-01-01 → 2022-09-30−¥14m
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-09-30¥2.4bn
jpcrp040300-q3r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-09-30−¥42m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-09-30¥3.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-09-30−¥1.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 365
ItemContextValueUnit
Income before income taxesPrior1YTDDuration-3180000000JPY
Income before income taxesCurrentYTDDuration-537000000JPY
Income taxes currentPrior1YTDDuration8000000JPY
Income taxes currentCurrentYTDDuration11000000JPY
Income taxes deferredPrior1YTDDuration-6000000JPY
Income taxes deferredCurrentYTDDuration14000000JPY
Income taxesPrior1YTDDuration1000000JPY
Income taxesCurrentYTDDuration25000000JPY
Profit lossPrior1YTDDuration-3182000000JPY
Profit lossCurrentYTDDuration-562000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-3182000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-562000000JPY
Profit lossPrior1YTDDuration-3182000000JPY
Profit lossCurrentYTDDuration-562000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration－JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration152000000JPY
Foreign currency translation adjustment net of tax ociPrior1YTDDuration161000000JPY
Foreign currency translation adjustment net of tax ociCurrentYTDDuration92000000JPY
Other comprehensive incomePrior1YTDDuration161000000JPY
Other comprehensive incomeCurrentYTDDuration244000000JPY
Comprehensive incomePrior1YTDDuration-3021000000JPY
Comprehensive incomeCurrentYTDDuration-318000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-3021000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-318000000JPY
Write downs of inventoriesPrior1YTDDuration555000000JPY
Write downs of inventoriesCurrentYTDDuration234000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember2407000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember976000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember5000000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember3389000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration3389000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember2407000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember976000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember5000000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember3389000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration3389000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22560-000PharmaceuticalsBusinessReportableSegmentsMember-42000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22560-000InfectionControlBusinessReportableSegmentsMember-1800000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E22560-000OtherBusinessLinesReportableSegmentsMember-14000000JPY
Operating incomePrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember-1856000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-893000000JPY
Operating incomePrior1YTDDuration-2750000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass